TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer

Here we summarize 10 years of effort in the development of a biomedical innovation with global projections. This innovation consists of a novel method for the production of therapeutic dendritic-like cells called Tumor Antigen Presenting Cells (TAPCells®). TAPCells-based immunotherapy was tested in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Salazar-Onfray,Flavio, Pereda,Cristián, Reyes,Diego, López,Mercedes N
Lenguaje:	English
Publicado:	Sociedad de Biología de Chile 2013
Materias:	Dendritic Cells Cancer Immunotherapy Melanoma Vaccine Technology Transfer Biotechnology
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602013000400014
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0716-97602013000400014
record_format	dspace
spelling	oai:scielo:S0716-976020130004000142014-02-05TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancerSalazar-Onfray,FlavioPereda,CristiánReyes,DiegoLópez,Mercedes N Dendritic Cells Cancer Immunotherapy Melanoma Vaccine Technology Transfer Biotechnology Here we summarize 10 years of effort in the development of a biomedical innovation with global projections. This innovation consists of a novel method for the production of therapeutic dendritic-like cells called Tumor Antigen Presenting Cells (TAPCells®). TAPCells-based immunotherapy was tested in more than 120 stage III and IV melanoma patients and 20 castration-resistant prostate cancer patients in a series of phase I and I/II clinical trials. TAPCells vaccines induced T cell-mediated memory immune responses that correlated with increased survival in melanoma patients and prolonged prostate-specific antigen doubling time in prostate cancer patients. Importantly, more than 60% of tested patients showed a Delayed Type Hypersensitivity (DTH) reaction against the lysates, indicating the development of anti-tumor immunological memory that correlates with clinical benefits. The in vitro analysis of the lysate mix showed that it contains damage-associated molecular patterns such as HMBG-1 protein which are capable to improve, through Toll-like receptor-4, maturation and antigen cross-presentation of the dendritic cells (DC). In fact, a Toll-like receptor-4 polymorphism correlates with patient clinical outcomes. Moreover, Concholepas concholepas hemocyanin (CCH) used as adjuvant proved to be safe and capable of enhancing the immunological response. Furthermore, we observed that DC vaccination resulted in a three-fold increase of T helper-1 lymphocytes releasing IFN-γ and a two-fold increase of T helper-17 lymphocytes capable of producing IL-17 in DTH+ with respect to DTH- patients. Important steps have been accomplished for TAPCells technology transfer, including patenting, packaging and technology assessment. Altogether, our results indicate that TAPCells vaccines constitute an exceptional Chilean national innovation of international value.info:eu-repo/semantics/openAccessSociedad de Biología de ChileBiological Research v.46 n.4 20132013-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602013000400014en10.4067/S0716-97602013000400014
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	Dendritic Cells Cancer Immunotherapy Melanoma Vaccine Technology Transfer Biotechnology
spellingShingle	Dendritic Cells Cancer Immunotherapy Melanoma Vaccine Technology Transfer Biotechnology Salazar-Onfray,Flavio Pereda,Cristián Reyes,Diego López,Mercedes N TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer
description	Here we summarize 10 years of effort in the development of a biomedical innovation with global projections. This innovation consists of a novel method for the production of therapeutic dendritic-like cells called Tumor Antigen Presenting Cells (TAPCells®). TAPCells-based immunotherapy was tested in more than 120 stage III and IV melanoma patients and 20 castration-resistant prostate cancer patients in a series of phase I and I/II clinical trials. TAPCells vaccines induced T cell-mediated memory immune responses that correlated with increased survival in melanoma patients and prolonged prostate-specific antigen doubling time in prostate cancer patients. Importantly, more than 60% of tested patients showed a Delayed Type Hypersensitivity (DTH) reaction against the lysates, indicating the development of anti-tumor immunological memory that correlates with clinical benefits. The in vitro analysis of the lysate mix showed that it contains damage-associated molecular patterns such as HMBG-1 protein which are capable to improve, through Toll-like receptor-4, maturation and antigen cross-presentation of the dendritic cells (DC). In fact, a Toll-like receptor-4 polymorphism correlates with patient clinical outcomes. Moreover, Concholepas concholepas hemocyanin (CCH) used as adjuvant proved to be safe and capable of enhancing the immunological response. Furthermore, we observed that DC vaccination resulted in a three-fold increase of T helper-1 lymphocytes releasing IFN-γ and a two-fold increase of T helper-17 lymphocytes capable of producing IL-17 in DTH+ with respect to DTH- patients. Important steps have been accomplished for TAPCells technology transfer, including patenting, packaging and technology assessment. Altogether, our results indicate that TAPCells vaccines constitute an exceptional Chilean national innovation of international value.
author	Salazar-Onfray,Flavio Pereda,Cristián Reyes,Diego López,Mercedes N
author_facet	Salazar-Onfray,Flavio Pereda,Cristián Reyes,Diego López,Mercedes N
author_sort	Salazar-Onfray,Flavio
title	TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer
title_short	TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer
title_full	TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer
title_fullStr	TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer
title_full_unstemmed	TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer
title_sort	tapcells, the chilean dendritic cell vaccine against melanoma and prostate cancer
publisher	Sociedad de Biología de Chile
publishDate	2013
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602013000400014
work_keys_str_mv	AT salazaronfrayflavio tapcellsthechileandendriticcellvaccineagainstmelanomaandprostatecancer AT peredacristian tapcellsthechileandendriticcellvaccineagainstmelanomaandprostatecancer AT reyesdiego tapcellsthechileandendriticcellvaccineagainstmelanomaandprostatecancer AT lopezmercedesn tapcellsthechileandendriticcellvaccineagainstmelanomaandprostatecancer
_version_	1718441508759142400

TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer

Ejemplares similares